PHOENIXVILLE, PA -- 05/01/08 --
In the news release, "Bilcare Global
Clinical Supplies Forms Corporate Advisory Board; Inducts Former Pfizer
President and the Executive Director of Waterloo Institute of
Nanotechnology as Members," issued earlier today by Bilcare, we are advised
by the company that the fifth sentence of the second paragraph should read
"Dr. LaMattina serves on the Board of Trustees of Boston College" rather
than "Dr. LaMattina serves on the Board of Trustees of Boston College and
the Board of Trustees of Worcester Polytechnic Institute" as originally
issued. Complete corrected text follows.
Bilcare Global Clinical Supplies Forms Corporate Advisory Board; Inducts
Former Pfizer President and the Executive Director of Waterloo Institute of
Nanotechnology as Members
PHOENIXVILLE, PA--(April 30, 2008) - Bilcare Global Clinical Supplies, a
leading single-source provider of clinical trial services, has formed its
first corporate Advisory Board. Bilcare Limited's Chairman and Managing
Director Mohan Bhandari announced former Pfizer President John LaMattina,
Ph.D., and Waterloo Institute of Nanotechnology Executive Director Arthur
Carty, Ph.D., D.Sc., as the board's inaugural members. Dr. LaMattina will
serve as its Chairman. The advisory board was created to provide the
Bilcare GCS Senior Management Team with independent scientific industry
expertise and insight to assist in the accomplishment of scientific and
business objectives in support of the company's global mission. "The
formation of our corporate Advisory Board is another major milestone in our
mission to make Bilcare GCS the global leader in the clinical trial
supplies arena," said Bhandari. "The addition of these accomplished members
will prove to be a tremendous asset to research and innovation initiatives
of our company."
Dr. LaMattina had a distinguished 30-year career at Pfizer where he held
various positions, including Senior Vice President of Pfizer Inc., and
President of Pfizer Global Research and Development. In this role, Dr.
LaMattina oversaw the drug discovery and development efforts of more than
12,000 colleagues in the United States, Europe and Asia. Dr. LaMattina is
the author of 23 scientific publications and holds 15 U.S. patents. He is
the 2004 recipient of the American Diabetes Association Award for
Leadership and Commitment in the Fight Against Diabetes. Dr. LaMattina
serves on the Board of Trustees of Boston College. "I am honored to be on
the corporate Advisory Board of a company that is on the rise and gaining
well-deserved recognition throughout the industry," said LaMattina. "I am
confident that the Advisory Board will play a pivotal role in the future
success of Bilcare's contribution to the clinical research industry."
Dr. Carty is the first Executive Director of the Waterloo Institute of
Nanotechnology and the former National Science Advisor to Canada's Prime
Minister. A noted academic, Dr. Carty had a distinguished career as the
President of the National Research Council of Canada from 1994 to 2004
after which he was appointed as the National Science Advisor. Prior to his
recent return to the institute, Dr. Carty spent 27 years as a professor of
chemistry at the University of Waterloo, serving as Chairman of the
chemistry department and Dean of Research. He has authored more than 285
papers in refered journals and multiple book chapters and review articles,
and also has five patents. Dr. Carty is a distinguished member of multiple
boards including two for the Networks of Centres of Excellence and Genome
Canada. Dr. Carty is both an Officer of the Order of Canada and Officer de
L'Ordre National du Merite of France. "Serving on the corporate Advisory
Board is an honor and comes with great responsibility," said Carty. "I am
committed to providing technology and biotech expertise I can to Bilcare
GCS to further its business objectives."
"I am certain that both of our Board members with their extensive
knowledge, experience, and business networks will provide immense benefits
to our company," said Bilcare GCS CEO Vito Mangiardi. "We are honored to
have Dr. LaMattina and Dr. Carty as an integral part of the Bilcare team
and look forward to a long association with them and to their successful
contribution especially in the areas of technology, research and
innovation."
Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with
clinical trial materials support, services and complete project management.
Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical
trial materials (CTM) satisfy a broad range of requirements, from
pre-formulation research and development, analytical services and clinical
supplies packaging and labeling, to IVRS, controlled temperature (cold and
frozen chain) CTM storage, distribution worldwide, and returns and
destructions accountability.
For more information about Bilcare Global Clinical Supplies, please visit
our website at
www.BilcareGCS.com.
Media Contacts:
Deborah Buscarino
Director of Marketing
Phone: 610-422-3204
Fax: 610-935-4321
E-mail: Email Contact
Vito Mangiardi
Chief Executive Officer
Bilcare Global Clinical Supplies
Phone: 610-551-2035
Fax: 610-935-4321
E-mail: Email Contact
